The global nuclear medicine market was valued at USD 7.44 Billion in 2025, driven by the increasing prevalence of cancer and cardiovascular disease across the globe. The market is anticipated to grow at a CAGR of 11.10% during the forecast period of 2026-2035 to achieve a value of USD 21.32 Billion by 2035.
Base Year
Historical Period
Forecast Period
Rising adoption of radioligand therapies for targeted cancer treatment is expected to significantly drive the nuclear medicine market growth over the forecast period, especially in oncology-focused regions.
Technological advancements in radiopharmaceutical delivery systems and increased clinical research funding are bolstering innovation and accelerating nuclear medicine development worldwide.
Strategic collaborations between pharmaceutical companies and nuclear medicine developers are expanding radiopharmaceutical pipelines, enhancing accessibility, and boosting market value globally.
Compound Annual Growth Rate
11.1%
Value in USD Billion
2026-2035
*this image is indicative*
Nuclear medicine is a specialized field of medical imaging and therapy that uses small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and treat various diseases. These substances are introduced into the body by injection, ingestion, or inhalation and are designed to target specific organs or cellular receptors. Imaging techniques like PET and SPECT allow physicians to visualize internal structures and assess organ function. In therapy, nuclear medicine delivers targeted radiation to treat conditions such as cancer, offering minimally invasive, highly effective solutions with reduced side effects compared to traditional treatments.
Advances in Clinical Trials to Boost Market Growth
Growing investments in radiopharmaceutical innovation and the rising global incidence of metastatic cancers are among the key drivers pushing the nuclear medicine market forward. For instance, in March 2025, the nuclear medicine division at Gustave Roussy, in collaboration with DITEP (Department of Therapeutic Innovation and Early Trials), launched its first patient treatment as part of a Phase I clinical trial using [177Lu] Lu-NeoB. The radiopharmaceutical targets the bombesin receptor, often overexpressed in cancers such as breast cancer. This milestone marks a major step in nuclear medicine clinical research in Europe. The study is expected to pave the way for more targeted, receptor-specific therapies and expand clinical trial activity, accelerating regional and global market growth in the forecast period.
Increasing Collaborations to Meet Rising Nuclear Medicine Market Demand
Surging demand for personalised oncology treatments and technological advances in alpha-emitting isotopes are fostering rapid development within the market. For instance, in October 2024, Sanofi and Orano Med announced a strategic collaboration to accelerate the creation of next-generation radioligand therapies. The venture focused on designing and clinically advancing radiopharmaceuticals based on lead-212 isotopes, targeting rare cancers. Building on Orano Med’s radioligand expertise, the partnership included the advancement of the late-stage candidate AlphaMedix. This alliance is poised to catalyse innovation in alpha therapy, expand treatment options for hard-to-treat cancers, and significantly drive growth and diversification in the market.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
"Nuclear Medicine Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Application
Market Breakup by End User
Market Breakup by Region
PET Radiopharmaceuticals to Dominate the Segmentation by Type
Positron emission tomography (PET) radiopharmaceuticals are poised to lead the market by type due to their superior imaging capabilities, early disease detection potential, and expanding oncology applications. F-18, one of the most widely used PET isotopes, plays a pivotal role in cancer diagnosis, neurology, and cardiology. Increasing prevalence of cancer, improved availability of PET scanners, and growing adoption of personalised medicine are key market drivers. Ongoing advancements in PET tracer development and government-backed diagnostic infrastructure investments will further boost this segment’s dominance in the forecast period, enhancing clinical precision and elevating the global nuclear medicine market value.
Oncology Segment to Lead the Nuclear Medicine Market Segmentation by Application
Oncology is expected to dominate the market by application, driven by rising global cancer incidence and increasing demand for early and accurate tumour detection. As per the analysis by Expert Market Research, the oncology drugs market is expected to grow at a CAGR of 13.2% during the forecast period of 2025-2034 . Nuclear medicine, particularly radioligand therapy and PET/CT imaging, is crucial for tumour localisation, staging, and treatment monitoring. The growth is reinforced by recent advancements in radiopharmaceuticals targeting specific cancer biomarkers and continued research investments. As the cancer burden rises and nuclear imaging becomes a standard in oncological protocols, this segment will continue to capture the largest share, strongly propelling the nuclear medicine market’s expansion during the forecast period.
Hospitals and Clinics to Hold a Significant Nuclear Medicine Market Share by End User
Hospitals and clinics are likely to dominate the market by end user, owing to their comprehensive infrastructure for advanced imaging and treatment procedures. These facilities offer integrated diagnostic and therapeutic services, making them the primary point of care for patients undergoing nuclear medicine procedures. Increasing cancer, cardiac, and neurological cases globally, coupled with hospital-based adoption of radioligand therapies and government funding for nuclear imaging, supports growth. Furthermore, expansion of nuclear medicine departments and enhanced access to isotopes in hospital settings will maintain this segment’s leadership in driving future market value and technological adoption.
North America is expected to command the largest share in the global nuclear medicine market due to its extensive clinical research infrastructure, strong regulatory support for radiopharmaceutical approvals, and early adoption of advanced imaging modalities. The presence of robust manufacturing capabilities, particularly for isotopes like F-18 and Lu-177, supports steady supply. Reimbursement policies and national programmes promoting molecular imaging bolster clinical usage. Europe follows closely, propelled by expanding radioisotope production and cross-border research initiatives. Asia-Pacific shows promising growth, driven by increasing healthcare investments in India and Japan. Meanwhile, Latin America and the Middle East & Africa are gradually advancing through public-private collaborations, though slower infrastructure development and access limitations restrict rapid expansion in these emerging regions.
The key features of the market report comprise patent analysis, clinical trials analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
GE Healthcare, headquartered in Chicago, Illinois, was established in 1994 as a subsidiary of General Electric. The company is a global leader in medical technology and diagnostics, including nuclear medicine solutions. GE Healthcare offers a wide range of molecular imaging systems, such as PET and SPECT scanners, and radiopharmaceuticals used in diagnosing and managing conditions like cancer, neurological disorders, and cardiovascular diseases. With continuous innovation and AI-powered imaging tools, the company plays a significant role in advancing precision diagnostics and personalised patient care in the nuclear medicine field.
Founded in 1971 and headquartered in Dublin, Ohio, Cardinal Health is a leading global healthcare services and products company. It plays a crucial role in the nuclear medicine market through its Nuclear & Precision Health Solutions division. The company operates one of the largest radiopharmacy networks in the United States, offering radiopharmaceuticals used in PET and SPECT imaging. Cardinal Health supports hospitals and clinics with efficient radiotracer supply, quality control, and logistics, enhancing diagnostic capabilities in oncology, neurology, and cardiology. Its vast distribution infrastructure makes it a trusted partner in time-sensitive radiopharmaceutical delivery.
Curium is a global nuclear medicine company established in 2017 and headquartered in Paris, France, and St. Louis, Missouri. Formed through the merger of IBA Molecular and Mallinckrodt’s nuclear medicine business, Curium specialises in manufacturing and distributing diagnostic and therapeutic radiopharmaceuticals. Its robust product portfolio includes SPECT and PET tracers, particularly Tc-99m generators and I-131-based therapeutics. The company serves over 14 million patients annually, operating through a strong network of radiopharmacies and production facilities across Europe and North America. Curium is widely recognised for maintaining high-quality standards and expanding access to nuclear medicine worldwide.
Bayer AG, a German multinational founded in 1863 and headquartered in Leverkusen, Germany, has a longstanding presence in pharmaceuticals, including nuclear medicine. The company is renowned for its innovation in targeted radioligand therapies, particularly in oncology. Bayer’s key nuclear medicine product, Xofigo® (radium-223 dichloride), is used in treating metastatic prostate cancer. With its growing oncology pipeline and investment in theranostic approaches, Bayer is actively expanding into next-generation radiopharmaceuticals. The company’s research collaborations and acquisitions reflect its strategic commitment to enhancing precision medicine and transforming patient outcomes in the global nuclear medicine landscape.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Lantheus Holdings, Inc., Bracco Imaging S.P.A., Pharmalogic Holdings Corp., Nordion Inc., Isotope JSC, and Siemens Healthineers.
Upto 15% Off
USD
$5499 $4949
$3299 $2969
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share